Live Breaking News & Updates on Professor Quek Swee Tian|Page 1

 E-Mail
Neuroendocrine tumours are cancers that begin in specialised cells called neuroendocrine cells. These cells have traits similar to those of nerve cells and hormone-producing cells. Neuroendocrine tumours, while rare, can occur anywhere in the body. Most affect the cardiothoracic region, eg lungs, appendix, small intestine, pancreas as well as the rectum. There are many types of neuroendocrine tumours: some grow slowly while others develop very rapidly.
Neuroendocrine tumors are characterised by abundant production of somatostatin receptor 2, a naturally circulating hormone that is an important target for scientists studying new treatment approaches.
Peptide Receptor Radionuclide Therapy (PRRT) is the most commonly used treatment for refractive neuroendocrine cancers, delivering cancer-killing radioactive substances directly to tumour sites. This treatment provides symptomatic relief, stopping or slowing tumour growth and improving overall survival for patients ....

Shawn Chen Xiaoyuan , Molecular Targeting Technologies Inc , Journal Of Nuclear Medicine , Chinese Academy Of Medical Science , National University Hospital , Yong Loo Lin School Of Medicine , Department Of Biomedical Engineering , Drug Administration , Union Medical College Hospital , National University Of Singapore , Department Of Diagnostic Radiology , Receptor Radionuclide Therapy , Peking Union Medical College Hospital , Chinese Academy , Medical Science , Professor Shawn Chen Xiaoyuan , Diagnostic Radiology , Yong Loo Lin School , National University , Prof Chen , Biomolecular Engineering , Biomedical Engineering , Nuclear Medicine , Professor Quek Swee Tian , Molecular Targeting Technologies , Investigational New Drug ,